Patients with metastatic cancer undergoing chemotherapy with fibroblast growth factor receptor (FGFR) inhibitors may experience a novel ocular toxicity, a new case series from Spain suggests, according to a report in Medscape.
"Subfoveal neurosensory retinal detachment may occur in association with pan-FGFR inhibitors treatment for metastatic cancer. Isolated subfoveal lesions and longer persistence of SRF (subretinal fluid) are features that may help in differentiating this entity from MEK retinopathy," lead author Dr. Daniel Velazquez-Villoria of POVISA Hospital, in Pontevedra, and colleagues write.
"The patients on these agents have cancer, and quality of life is as important as duration of life. Knowing that these agents can cause ocular problems will enable us to better monitor these patients and also to possibly modify the agent to avoid these side effects," Dr. Jose S. Pulido, a professor of ophthalmology at Mayo Clinic in Rochester, Minnesota, told Reuters Health in an email.